Zacks Investment Research cut shares of CytomX Therapeutics (NASDAQ:CTMX) from a hold rating to a sell rating in a research note issued to investors on Monday, February 19th.
According to Zacks, “CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. “
Other equities analysts have also issued research reports about the company. BidaskClub raised CytomX Therapeutics from a hold rating to a buy rating in a research note on Friday, December 15th. Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a research report on Monday, October 23rd. They issued an overweight rating and a $35.00 price target on the stock. ValuEngine downgraded CytomX Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Finally, Citigroup assumed coverage on CytomX Therapeutics in a report on Friday, January 5th. They issued a buy rating and a $40.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $35.67.
In other news, Director Frederick W. Gluck sold 5,000 shares of CytomX Therapeutics stock in a transaction on Tuesday, December 26th. The stock was sold at an average price of $22.29, for a total value of $111,450.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $21.11, for a total value of $52,775.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 132,626 shares of company stock valued at $3,709,830. 8.00% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Macquarie Group Ltd. acquired a new position in shares of CytomX Therapeutics during the third quarter worth about $107,000. Bank of Montreal Can acquired a new position in shares of CytomX Therapeutics during the fourth quarter worth about $124,000. Cubist Systematic Strategies LLC acquired a new position in shares of CytomX Therapeutics in the second quarter worth about $174,000. Voya Investment Management LLC acquired a new position in shares of CytomX Therapeutics in the second quarter worth about $203,000. Finally, MetLife Investment Advisors LLC acquired a new position in shares of CytomX Therapeutics in the fourth quarter worth about $245,000. Institutional investors own 78.50% of the company’s stock.
WARNING: This report was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2018/03/14/cytomx-therapeutics-ctmx-downgraded-to-sell-at-zacks-investment-research-2.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.